低壁剪压力通过动脉铁积累促进动脉瘤
Lei Zheng1,2, Zhenxi Zhang1, Yutong Liu1
1Department of Vascular Surgery (L.Z., Z.Z., Y.L., B.Z., Z.C., J.C., T.Q.), Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, China.
Arteriosclerosis, thrombosis, and vascular biology
|October 2, 2025
概括
低壁剪压力 (WSS) 通过导致动脉中铁的积累促进动脉样硬化. 铁化剂和向铁调节蛋白2 (IRP2) 可以减少这种铁积累并减缓疾病的进展.
科学领域:
- 心血管生物学 心血管生物学
- 动脉样硬化研究 动脉样硬化研究
- 内皮细胞生物学 内皮细胞生物学
背景情况:
- 低壁切削应力 (WSS) 在动脉分叉和曲线损害内皮细胞,有助于动脉样硬化发展.
- 在动脉样硬化斑块中观察到铁的积累,但潜在的机制和影响仍然不清楚.
研究的目的:
- 研究低WSS诱导的铁积累在动脉样硬化中的作用.
- 评估铁化和向铁代谢的治疗潜力,以缓解动脉样硬化.
主要方法:
- 利用小鼠模型 (部分动脉绑定,Apoe淘汰与内皮IRP2淘汰) 和体外内皮细胞培养物来模拟低WSS.
- 管理铁化剂 (Hinokitiol) 并使用基因淘汰/淘汰策略用于IRP2和Apoe.
- 研究铁含量,蛋白质表达 (IRP2,炎症标志物,HIFs) 和动脉样硬化进展.
主要成果:
- 低WSS导致阴道动脉中慢性铁积累,改变内皮铁代谢蛋白表达,特别是IRP2.2.
- 击倒IRP2增加了炎症和缺氧诱导因子 (HIF),在Apoe淘汰赛小鼠中加剧了动脉样硬化.
- 铁合剂Hinokitiol减少了铁的积累和动脉样硬化进展;HIF抑制剂抑制了IRP2淘汰赛诱导的动脉样硬化恶化.
结论:
- 低WSS诱导的内皮铁失调通过动脉铁积累和异常蛋白质表达促进动脉样硬化.
- 铁化疗法是一种有前途的策略,可以缓解与低WSS相关的动脉样硬化的发病和进展.
相关概念视频
01:30Atherosclerosis I: Introduction
923
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
923
01:38Inflammation
61.7K
Overview
61.7K
01:26Coronary Artery Disease II: Pathophysiology
374
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
374
01:26Atherosclerosis III: Management
321
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
321
01:30Peripheral Artery Disease I: Introduction
314
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
314